More on RCUS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $29.73 |
|
|||
| Open | $30.02 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $30.17 | ||||
| Day Low | $28.33 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 1,230,517 | ||||
- H.C. Wainwright Reiterates Buy Rating on Arcus Biosciences (RCUS)
- Arcus, AVEO to test kidney cancer drug combo in new trial
- Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
- Arcus and Summit team up to test kidney cancer drug combo
- Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
- Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
- Arcus Biosciences (RCUS) PT Raised to $45 at H.C. Wainwright
- Form 144 Arcus Biosciences, Inc. Filed by: Jaen Juan C.
- Form 4 Arcus Biosciences, Inc. For: Jul 09 Filed by: Jaen Juan C.
- Form 144 Arcus Biosciences, Inc. Filed by: Jaen Juan C.
Entities mentioned with RCUS
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- 13G | View Related Stories »
- FDA | View Related Stories »
- Show More...
